Antifungal Susceptibility and Genotypic Analysis of cyp51A Mutations in Aspergillus fumigatus Isolates in Malaysia
DOI: https://doi.org/10.2147/idr.s452619
2024-05-29
Infection and Drug Resistance
Abstract:Xue Ting Tan, Nurin Nazirah Binti Mokhtar, Shirley Yi Fen Hii, Fairuz Amran Bacteriology Unit, Infectious Diseases Research Centre, Institute for Medical Research, National Institute of Health, Ministry of Health Malaysia, Setia Alam, Selangor, Malaysia Correspondence: Xue Ting Tan, Bacteriology unit, Infectious Diseases Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, No. 1, Jalan Setia Murni U13/52 Seksyen U13, Setia Alam, 40170, Selangor, Malaysia, Email Purpose: Azole resistance in Aspergillus fumigatus poses a significant challenge in the management of invasive aspergillosis. This study aimed to investigate the antifungal susceptibility and cyp51A mutation profiles of A. fumigatus isolates in Malaysia. Patients and Methods: Sixty clinical A. fumigatus isolates were collected and subjected to antifungal susceptibility testing (AFST) and molecular analysis. The antifungal susceptibility testing was performed according to CLSI M38 guideline. The geometric mean (GM) minimum inhibitory concentration (MIC), MIC 50 /MIC 90 for voriconazole, itraconazole, posaconazole, amphotericin B, and isavuconazole against A. fumigatus in non-invasive cases and invasive cases were calculated. In addition, the presence of cyp51A mutations was also identified. Results: The present study revealed an overall resistance rate of 6.7% among the isolates. In non-invasive cases, isavuconazole and posaconazole demonstrated the lowest GM MIC of 0.08 μg/mL. Following them were itraconazole, voriconazole, and amphotericin B with concentrations of 0.15μg/mL, 0.16μg/mL and 0.90μg/mL, respectively. Similarly, in invasive cases, isavuconazole and posaconazole exhibited the lowest GM MIC of 0.09μg/mL. Following them were itraconazole, voriconazole, and amphotericin B with concentrations of 0.14μg/mL, 0.17μg/mL and 0.80μg/mL, respectively. Genotypic analysis revealed various cyp51A mutations, including F46Y, M172V, N248K, R34L, V244A, V244S, and E427K. However, not all mutations corresponded to antifungal resistance. Conclusion: The majority of clinical Aspergillus fumigatus isolates demonstrated susceptibility to the antifungal agents tested, with isavuconazole and posaconazole demonstrating the lowest MIC values. However, cyp51A mutations were discovered without a consistent correlation to antifungal resistance, emphasising the need for additional research. Keywords: invasive aspergillosis, minimum inhibitory concentration, voriconazole, isavuconazole, posaconazole Aspergillus is a saprophytic fungus that is widely distributed throughout our living environment. 1 The infectious propagule of Aspergillus is conidia 2 that can be carried by air currents and inhaled into the lungs through the mouth and nose. 1,2 Daily exposure to the conidia can result in several clinical conditions, including Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), allergic sinusitis, aspergilloma, and invasive aspergillosis (IA). 1,2 IA is a significant opportunistic infection with high morbidity and mortality rates. 3,4 This severe and life-threatening form of the disease always affect immunocompromised people who receiving chemotherapy or organ-transplant patients or those infected with acquired immunodeficiency syndrome (AIDS). IA has a high death rate and can affect several organs, such as kidneys, liver, brain, and lungs. However, the confirmation of IA cases is suggested to have microscopic analysis, molecular diagnosis or culture detection of the organism from sterile material. 5–7 Every year, more than 300,000 people was affected by IA, with 58–99% mortality rate. 8–10 In Malaysia, the rate of aspergillosis was estimated 3.3% per 100,000 population. 11 Among many species of Aspergillus , the most common aetiologic agent of IA is Aspergillus fumigatus . 12–15 Triazole antifungals are strongly recommended for the treatment of aspergillosis. 16,17 However, the emergence of azole resistance in A. fumigatus poses a significant threat to the treatment outcomes. 18 Mutations in the cyp51A gene, which codes for the target enzyme lanosterol 14-demethylase, are the main cause of azole resistance in A. fumigatus . 19,20 These mutations can differ in frequency and geographic distribution, which emphasizes the importance of regional research in determining the resistance landscape in certain places. For example, G54W, M220I/V/T and F219C were reported in Germany; 21 while F46Y, M172V, N248T, D255E and E4 -Abstract Truncated-
pharmacology & pharmacy,infectious diseases